Highlights LigaChem Biosciences Inc.

Equities

A141080

KR7141080002

End-of-day quote Korea S.E. Other stock markets 23:00:00 28/05/2024 BST			5-day change	1st Jan Change
61,900 ^KRW	-2.37%		-9.64%	-4.77%

05-16	LigaChem Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-08	NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	04-08	CI
Pan Orion Corp. Ltd. completed the acquisition of 4.93% stake in LegoChem Biosciences, Inc. from Kim Yong Ju and Park Se Jin.	03-28	CI
Samsung Biologics Collaborates with LegoChem Biosciences on ADC Development and Manufacturing	02-09	MT
Orion Set to Acquire 25% Stake in LegoChem Biosciences	01-17	MT
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	12-28	CI
LegoChem Biosciences, Inc.'s Equity Buyback announced on June 28, 2023, has expired with 140,000 shares, representing 0.53% for KRW 4,879.08 million.	12-27	CI
J&J: licensing agreement with Korea's LegoChem in ADCs	12-27	CF
Legochem Biosciences Announces License Agreement for Lcb84 Trop2-Targeted ADC	12-26	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
BostonGene and LegoChem Biosciences, Inc. Announce Collaboration to Support Phase I/II Study of LCB84, TROP2-Directed ADC, in Patients with Advanced Cancers	11-07	CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	04/10/23	CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	04/10/23	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
LegoChem Biosciences, Inc. announces an Equity Buyback for KRW 5,000 million worth of its shares.	28/06/23	CI
LegoChem Biosciences, Inc. authorizes a Buyback Plan.	27/06/23	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23	CI
Legochem Biosciences and Amgen Enter into A Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates	23/12/22	CI
NextCure, LegoChem Biosciences to Collaborate on Development of Antibody Drug Conjugates	16/11/22	MT
NextCure, Inc. and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates	15/11/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights LigaChem Biosciences Inc.

Equities

A141080

KR7141080002

Highlights

Filters